Clinical Trial Update: Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the combination of dronabinol and Epidiolex (cannabidiol) to manage residual symptoms during buprenorphine initiation for opioid use …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• Dronabinol (Marinol) (dronabinol)
• EPIDIOLEX (Cannabidiol)

Snippet

Sponsor: Montefiore Medical Center | Conditions: Opioid Use Disorder | Phase 3 | Status: NOT_YET_RECRUITING